What is the treatment for osteoporosis?

Denosumab is a Specific Nuclear Factor κ B Receptor Activator Ligand (RANKL) inhibitor, can significantly reduce bone resorption, increase bone mineral density, reduce the risk of vertebral body, non-vertebral body and hip fractures, is one of the effective drugs in the treatment of osteoporosis. Denosumab is reliable in the treatment of osteoporosis. Denosumab is a Specific Nuclear Factor κ B Receptor Activator Ligand (RANKL) inhibitor, can significantly reduce bone resorption, increase bone density, reduce the risk of vertebral body, non-vertebral body and hip fractures, is one of the effective drugs for the treatment of osteoporosis. The following are the reasons why denosumab is reliable in the treatment of osteoporosis: 1. The mechanism of action is clear: Denosumab reduces bone resorption and increases bone mineral density by inhibiting RANKL binding to RANK on osteoclast surfaces, reducing osteoclast formation, activation, and survival. 2. Significant clinical efficacy: Denosumab has been shown to significantly reduce the risk of vertebral, nonvertebral, and hip fractures and improve quality of life in patients with osteoporosis in multiple clinical trials. 3. Good safety: The incidence of adverse reactions of denosumab is low. Common adverse reactions include bone pain, fever, headache, etc., most of which are mild to moderate and mostly self-limited. It should be noted that detailed evaluation should be carried out before denosumab use, including bone mineral density, fracture risk, renal function, etc. Denosumab is not indicated for use in allergic, pregnant, or lactating women. In summary, denosumab is a reliable treatment for osteoporosis, but should be used only under the guidance of a physician. Patients should pay attention to the occurrence of adverse reactions during use, and seek medical attention in case of discomfort. At the same time, patients should also pay attention to supplement calcium and vitamin D to promote bone health.